Slingshot members are tracking this event:

Lipocine (LPCN) receives FDA CRL for the 2nd time regarding its refiled MA for testosterone replacement therapy candidate Tlando

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Additional Relevant Details The CRL identified one deficiency stating the efficacy trial did not meet the three secondary endpoints for maximal testosterone concentrations ("Cmax").
Slingshot Insights Explained
Catalyst Date
Occurred on:
Nov 11, 2019
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Testosterone Replacement Therapy, Tlando